Revance Therapeutics (RVNC)
(Delayed Data from NSDQ)
$3.29 USD
-0.28 (-7.84%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $3.35 +0.06 (1.82%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RVNC 3.29 -0.28(-7.84%)
Will RVNC be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for RVNC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RVNC
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Misses Revenue Estimates
Halozyme Therapeutics (HALO) Q4 Earnings Match Estimates
RVNC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Revance Therapeutics, Inc. (RVNC) Reports Q3 Earnings: What Key Metrics Have to Say
Revance Therapeutics, Inc. (RVNC) Reports Q2 Loss, Tops Revenue Estimates
Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates
Other News for RVNC
Barclays Sticks to Their Buy Rating for Revance Therapeutics (RVNC)
OPI, RVNC and AQST are among after hour movers
AbbVie working with FDA after reports of fake Botox versions
Commit To Buy Revance Therapeutics At $2.50, Earn 20.9% Annualized Using Options
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting